AU764992B2 - TNF-derived peptides for use in treating oedema - Google Patents

TNF-derived peptides for use in treating oedema Download PDF

Info

Publication number
AU764992B2
AU764992B2 AU56209/99A AU5620999A AU764992B2 AU 764992 B2 AU764992 B2 AU 764992B2 AU 56209/99 A AU56209/99 A AU 56209/99A AU 5620999 A AU5620999 A AU 5620999A AU 764992 B2 AU764992 B2 AU 764992B2
Authority
AU
Australia
Prior art keywords
tnf
peptide
oedema
peptides
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU56209/99A
Other languages
English (en)
Other versions
AU5620999A (en
Inventor
Alain Bloc
Patrick De Baetselier
Lucie Fransen
Rudolf Lucas
Jerome Pugin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lucas Rudolf Dr
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of AU5620999A publication Critical patent/AU5620999A/en
Application granted granted Critical
Publication of AU764992B2 publication Critical patent/AU764992B2/en
Assigned to LUCAS, Rudolf Dr. reassignment LUCAS, Rudolf Dr. Alteration of Name(s) in Register under S187 Assignors: INNOGENETICS N.V.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU56209/99A 1998-08-14 1999-08-10 TNF-derived peptides for use in treating oedema Ceased AU764992B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870198 1998-09-18
EP98870222 1998-10-21
EP98870222 1998-10-21
PCT/EP1999/005806 WO2000009149A1 (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema

Publications (2)

Publication Number Publication Date
AU5620999A AU5620999A (en) 2000-03-06
AU764992B2 true AU764992B2 (en) 2003-09-04

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56209/99A Ceased AU764992B2 (en) 1998-08-14 1999-08-10 TNF-derived peptides for use in treating oedema

Country Status (20)

Country Link
US (2) US20030105021A1 (https=)
EP (3) EP1264599B1 (https=)
JP (1) JP4542266B2 (https=)
CN (1) CN1181886C (https=)
AT (2) ATE374039T1 (https=)
AU (1) AU764992B2 (https=)
BR (1) BR9912899A (https=)
CA (1) CA2334941C (https=)
CZ (1) CZ302862B6 (https=)
DE (2) DE69938743D1 (https=)
DK (1) DK1264599T3 (https=)
ES (1) ES2296872T3 (https=)
HU (1) HU227661B1 (https=)
IL (2) IL141064A0 (https=)
NZ (1) NZ509604A (https=)
PL (1) PL203706B1 (https=)
PT (1) PT1264599E (https=)
TR (1) TR200100338T2 (https=)
WO (1) WO2000009149A1 (https=)
ZA (1) ZA200100656B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PL2397151T3 (pl) * 2010-06-21 2015-10-30 Apeptico Forschung & Entwicklung Gmbh Leczenie powikłań naczyniowych cukrzycy
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US20160143266A1 (en) * 2013-04-23 2016-05-26 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US10925924B2 (en) 2014-03-18 2021-02-23 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115461356A (zh) 2020-05-08 2022-12-09 阿佩普蒂科研究和开发有限责任公司 用于预防或治疗covid-19的肽

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841759A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REZAIGUIA ET AL. J.CLINT.INVEST., (1997), 99(2), 325-335 *

Also Published As

Publication number Publication date
IL141064A0 (en) 2002-02-10
US20030105021A1 (en) 2003-06-05
CZ302862B6 (cs) 2011-12-21
CN1312724A (zh) 2001-09-12
AU5620999A (en) 2000-03-06
HK1051805A1 (en) 2003-08-22
IL141064A (en) 2009-09-01
ATE395072T1 (de) 2008-05-15
ZA200100656B (en) 2005-06-29
PT1264599E (pt) 2008-01-07
HUP0103117A2 (hu) 2001-12-28
CZ2001538A3 (cs) 2001-08-15
EP1247531A2 (en) 2002-10-09
ES2296872T3 (es) 2008-05-01
EP1247531A3 (en) 2002-12-18
EP1264599A1 (en) 2002-12-11
NZ509604A (en) 2003-05-30
CA2334941C (en) 2011-08-09
DK1264599T3 (da) 2008-02-04
CA2334941A1 (en) 2000-02-24
ATE374039T1 (de) 2007-10-15
WO2000009149A1 (en) 2000-02-24
DE69937206T2 (de) 2008-06-19
EP1264599B1 (en) 2007-09-26
PL345997A1 (en) 2002-01-14
DE69938743D1 (de) 2008-06-26
DE69937206D1 (de) 2007-11-08
EP1105152A1 (en) 2001-06-13
HU227661B1 (hu) 2011-10-28
US7258861B2 (en) 2007-08-21
JP2002522508A (ja) 2002-07-23
EP1247531B1 (en) 2008-05-14
PL203706B1 (pl) 2009-11-30
CN1181886C (zh) 2004-12-29
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
BR9912899A (pt) 2001-05-08
JP4542266B2 (ja) 2010-09-08
TR200100338T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
AU764992B2 (en) TNF-derived peptides for use in treating oedema
US11066458B2 (en) VEGF antagonist formulations suitable for intravitreal administration
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US5238919A (en) Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US9555080B2 (en) Medicament for therapeutic treatment and/or improvement of sepsis
KR20030060988A (ko) 펩타이드 및/또는 단백질, 및 치료제 및 예방제의 제조를위한 그들의 용도
JPH07509691A (ja) 安定なポリペプチド組成物
HK1051802A (en) Tnf-derived peptides for use in treating oedema
HK1051805B (en) Tnf-derived peptides for use in treating oedema
MXPA01001527A (en) Tnf-derived peptides for use in treating oedema
CN101730710A (zh) Vegf-d突变体及其用途
WO2012081711A1 (ja) 細胞遊走調節剤
WO1994004181A1 (en) Heparin neutralization with multimeric peptides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)